Patient-Related Risk Factors for Nausea and Vomiting with Standard Antiemetics in Patients with Breast Cancer Receiving Anthracycline-Based Chemotherapy: A Retrospective Observational Study

Hitoshi Kawazoe, Akari Murakami, Michiko Yamashita, Kanako Nishiyama, Kana Kobayashi-Taguchi, Saaya Komatsu, Reina Aoki, Erina Kusakabe, Haruna Yamasawa, Yoshihiro Yakushijin, Tomonori Nakamura, Yoshiaki Kamei

Research output: Contribution to journalArticle

Abstract

Purpose: The aim of this study was to identify a high-risk or low-risk population for chemotherapy-induced nausea and vomiting among patients with breast cancer treated with a current standard 3-drug antiemetic regimen and receiving anthracycline. Methods: We analyzed data from chemotherapy-naive Japanese patients with breast cancer, who had received the first cycle of anthracycline-based regimen and were treated with a 3-drug combination of aprepitant, palonosetron, and dexamethasone. This study was carried out at Ehime University Hospital (Toon, Japan) using electronic medical records from May 2011 to June 2017. The primary end point was complete response (CR), which was defined as no emesis and no use of rescue medication. Findings: A total of 103 patients were included in this study. The percentages of patients who had a CR in the overall, acute, and delayed phases were 35.0%, 40.8%, and 50.5%, respectively. Multivariate logistic regression analysis revealed that age <55 years and body mass index <27.5 kg/m2 were significantly associated with an increased risk for CR failure in the overall and acute phases. In contrast, a history of alcohol habit was significantly associated with a decreased risk for CR failure in overall phase. Implications: The present findings suggest that, among patients with breast cancer receiving anthracycline and treated with aprepitant, palonosetron, and dexamethasone, patients younger than 55 years and having a body mass index <27.5 kg/m2 are high-risk populations for chemotherapy-induced nausea and vomiting, whereas those with a history of habitual alcohol consumption is a low-risk one.

Original languageEnglish
JournalClinical Therapeutics
DOIs
Publication statusAccepted/In press - 2018 Jan 1

Fingerprint

Antiemetics
Anthracyclines
Nausea
Vomiting
Observational Studies
Retrospective Studies
aprepitant
Breast Neoplasms
Drug Therapy
Dexamethasone
Body Mass Index
Electronic Health Records
Drug Combinations
Alcohol Drinking
Population
Habits
Japan
Logistic Models
Regression Analysis
Alcohols

Keywords

  • anthracycline
  • breast cancer
  • chemotherapy-induced nausea and vomiting (CINV)
  • multivariate logistic regression analysis
  • risk factors

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Patient-Related Risk Factors for Nausea and Vomiting with Standard Antiemetics in Patients with Breast Cancer Receiving Anthracycline-Based Chemotherapy : A Retrospective Observational Study. / Kawazoe, Hitoshi; Murakami, Akari; Yamashita, Michiko; Nishiyama, Kanako; Kobayashi-Taguchi, Kana; Komatsu, Saaya; Aoki, Reina; Kusakabe, Erina; Yamasawa, Haruna; Yakushijin, Yoshihiro; Nakamura, Tomonori; Kamei, Yoshiaki.

In: Clinical Therapeutics, 01.01.2018.

Research output: Contribution to journalArticle

Kawazoe, Hitoshi ; Murakami, Akari ; Yamashita, Michiko ; Nishiyama, Kanako ; Kobayashi-Taguchi, Kana ; Komatsu, Saaya ; Aoki, Reina ; Kusakabe, Erina ; Yamasawa, Haruna ; Yakushijin, Yoshihiro ; Nakamura, Tomonori ; Kamei, Yoshiaki. / Patient-Related Risk Factors for Nausea and Vomiting with Standard Antiemetics in Patients with Breast Cancer Receiving Anthracycline-Based Chemotherapy : A Retrospective Observational Study. In: Clinical Therapeutics. 2018.
@article{949fb52e19464cebad401f5baa246b60,
title = "Patient-Related Risk Factors for Nausea and Vomiting with Standard Antiemetics in Patients with Breast Cancer Receiving Anthracycline-Based Chemotherapy: A Retrospective Observational Study",
abstract = "Purpose: The aim of this study was to identify a high-risk or low-risk population for chemotherapy-induced nausea and vomiting among patients with breast cancer treated with a current standard 3-drug antiemetic regimen and receiving anthracycline. Methods: We analyzed data from chemotherapy-naive Japanese patients with breast cancer, who had received the first cycle of anthracycline-based regimen and were treated with a 3-drug combination of aprepitant, palonosetron, and dexamethasone. This study was carried out at Ehime University Hospital (Toon, Japan) using electronic medical records from May 2011 to June 2017. The primary end point was complete response (CR), which was defined as no emesis and no use of rescue medication. Findings: A total of 103 patients were included in this study. The percentages of patients who had a CR in the overall, acute, and delayed phases were 35.0{\%}, 40.8{\%}, and 50.5{\%}, respectively. Multivariate logistic regression analysis revealed that age <55 years and body mass index <27.5 kg/m2 were significantly associated with an increased risk for CR failure in the overall and acute phases. In contrast, a history of alcohol habit was significantly associated with a decreased risk for CR failure in overall phase. Implications: The present findings suggest that, among patients with breast cancer receiving anthracycline and treated with aprepitant, palonosetron, and dexamethasone, patients younger than 55 years and having a body mass index <27.5 kg/m2 are high-risk populations for chemotherapy-induced nausea and vomiting, whereas those with a history of habitual alcohol consumption is a low-risk one.",
keywords = "anthracycline, breast cancer, chemotherapy-induced nausea and vomiting (CINV), multivariate logistic regression analysis, risk factors",
author = "Hitoshi Kawazoe and Akari Murakami and Michiko Yamashita and Kanako Nishiyama and Kana Kobayashi-Taguchi and Saaya Komatsu and Reina Aoki and Erina Kusakabe and Haruna Yamasawa and Yoshihiro Yakushijin and Tomonori Nakamura and Yoshiaki Kamei",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.clinthera.2018.10.004",
language = "English",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",

}

TY - JOUR

T1 - Patient-Related Risk Factors for Nausea and Vomiting with Standard Antiemetics in Patients with Breast Cancer Receiving Anthracycline-Based Chemotherapy

T2 - A Retrospective Observational Study

AU - Kawazoe, Hitoshi

AU - Murakami, Akari

AU - Yamashita, Michiko

AU - Nishiyama, Kanako

AU - Kobayashi-Taguchi, Kana

AU - Komatsu, Saaya

AU - Aoki, Reina

AU - Kusakabe, Erina

AU - Yamasawa, Haruna

AU - Yakushijin, Yoshihiro

AU - Nakamura, Tomonori

AU - Kamei, Yoshiaki

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: The aim of this study was to identify a high-risk or low-risk population for chemotherapy-induced nausea and vomiting among patients with breast cancer treated with a current standard 3-drug antiemetic regimen and receiving anthracycline. Methods: We analyzed data from chemotherapy-naive Japanese patients with breast cancer, who had received the first cycle of anthracycline-based regimen and were treated with a 3-drug combination of aprepitant, palonosetron, and dexamethasone. This study was carried out at Ehime University Hospital (Toon, Japan) using electronic medical records from May 2011 to June 2017. The primary end point was complete response (CR), which was defined as no emesis and no use of rescue medication. Findings: A total of 103 patients were included in this study. The percentages of patients who had a CR in the overall, acute, and delayed phases were 35.0%, 40.8%, and 50.5%, respectively. Multivariate logistic regression analysis revealed that age <55 years and body mass index <27.5 kg/m2 were significantly associated with an increased risk for CR failure in the overall and acute phases. In contrast, a history of alcohol habit was significantly associated with a decreased risk for CR failure in overall phase. Implications: The present findings suggest that, among patients with breast cancer receiving anthracycline and treated with aprepitant, palonosetron, and dexamethasone, patients younger than 55 years and having a body mass index <27.5 kg/m2 are high-risk populations for chemotherapy-induced nausea and vomiting, whereas those with a history of habitual alcohol consumption is a low-risk one.

AB - Purpose: The aim of this study was to identify a high-risk or low-risk population for chemotherapy-induced nausea and vomiting among patients with breast cancer treated with a current standard 3-drug antiemetic regimen and receiving anthracycline. Methods: We analyzed data from chemotherapy-naive Japanese patients with breast cancer, who had received the first cycle of anthracycline-based regimen and were treated with a 3-drug combination of aprepitant, palonosetron, and dexamethasone. This study was carried out at Ehime University Hospital (Toon, Japan) using electronic medical records from May 2011 to June 2017. The primary end point was complete response (CR), which was defined as no emesis and no use of rescue medication. Findings: A total of 103 patients were included in this study. The percentages of patients who had a CR in the overall, acute, and delayed phases were 35.0%, 40.8%, and 50.5%, respectively. Multivariate logistic regression analysis revealed that age <55 years and body mass index <27.5 kg/m2 were significantly associated with an increased risk for CR failure in the overall and acute phases. In contrast, a history of alcohol habit was significantly associated with a decreased risk for CR failure in overall phase. Implications: The present findings suggest that, among patients with breast cancer receiving anthracycline and treated with aprepitant, palonosetron, and dexamethasone, patients younger than 55 years and having a body mass index <27.5 kg/m2 are high-risk populations for chemotherapy-induced nausea and vomiting, whereas those with a history of habitual alcohol consumption is a low-risk one.

KW - anthracycline

KW - breast cancer

KW - chemotherapy-induced nausea and vomiting (CINV)

KW - multivariate logistic regression analysis

KW - risk factors

UR - http://www.scopus.com/inward/record.url?scp=85055739496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055739496&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2018.10.004

DO - 10.1016/j.clinthera.2018.10.004

M3 - Article

C2 - 30392814

AN - SCOPUS:85055739496

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

ER -